*ST益通 reported revenue of ¥0.35B for the period ended 2026-06-30, -14.8% year on year. Net income was ¥-0.03B, a -9.4% net margin on a 20.7% gross margin. The largest revenue line is 控制系统 at 52% of the total. Free cash flow for the period was ¥-0.07B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.35B | -14.8% |
| Gross profit | ¥0.07B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.03B | -174.6% |
| Gross margin | 20.7% | Net margin -9.4% |
| Revenue Q/Q | -42.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 控制系统 | ¥0.18B | 51.9% |
| 康复医疗器械 | ¥0.09B | 26.1% |
| 系统设备及其他 | ¥0.08B | 21.9% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.28B | 79.3% |
| R&D | ¥0.04B | 10.6% |
| SG&A | ¥0.09B | 26.5% |
| Tax & other | ¥0.01B | 3.4% |
| Item | Amount |
|---|---|
| Total assets | ¥3.12B |
| Total liabilities | ¥1.85B |
| Shareholders' equity | ¥1.27B |
| Equity / assets | 40.8% |
| Operating cash flow | ¥-0.06B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥-0.07B |
| Cash conversion (OCF / net income) | 511% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
富临精工 ・ 金石亚药 ・ 中泰股份 ・ 广生堂 ・ 清水源 ・ 鹏辉能源 ・ 美康生物 ・ 运达科技 ・ 鲍斯股份 ・ 金雷股份 ・ 双杰电气 ・ 康斯特
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies